Knockdown of FABP6 can significantly inhibit the proliferation and motility of BLCA cells, while downregulating the expression of cell cycle proteins such as CDK2 and CDK4 and blocking the AKT-mTOR signaling pathway, enhancing the therapeutic effect of cisplatin (76). Here, FABP6 is linked to bladder transitional cell carcinoma.